Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Refresh Optive · 1 trial · 1 indication
The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.
| Arm | Type | Description |
|---|---|---|
| Refresh Optive® Gel Drops | EXPERIMENTAL | Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| REFRESH LIQUIGEL® | ACTIVE_COMPARATOR | REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Name | Type | Description |
|---|---|---|
| Refresh Optive® Gel Drops | DRUG | Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| REFRESH LIQUIGEL® | DRUG | REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
Inclusion Criteria: * Current use of an artificial tear product * Visual acuity of at least 20/32 (while wearing glasses, if necessary). Exclusion Criteria: * Use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study * Cataract surgery, laser-assisted in si...
Top 20 of 34 competitors
Refresh Optive is used for dry eye syndromes. It is an investigational small molecule being developed by AbbVie Inc. for the treatment of dry eye disease. The drug is currently in Phase 3 clinical development, though the specific trial for this asset has been completed.
Refresh Optive is developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is being studied for the treatment of dry eye syndromes, a condition within the ophthalmology therapeutic area.
Refresh Optive is in Phase 3 clinical development. The drug is being investigated for the treatment of dry eye syndromes. While the Phase 3 trial has been completed, Refresh Optive remains an investigational drug and has not been approved for commercial use.
Refresh Optive has been studied in a Phase 3 clinical trial identified as NCT02280473. This trial, titled "A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease," was conducted in the United States and enrolled 188 participants. The study was completed and was randomized, double-blind, and active-controlled.
Yes, Refresh Optive is the same as Refresh Optive Gel Drops. The Phase 3 clinical trial NCT02280473 specifically evaluated Refresh Optive Gel Drops in patients with dry eye disease. The drug is being developed by AbbVie Inc. for the treatment of dry eye syndromes.